tetano
Editor, Senior Moderator
J Med Virol
. 2022 May 25.
doi: 10.1002/jmv.27885. Online ahead of print.
A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity
Peng Du[SUP] 1 [/SUP], Ning Li[SUP] 1 [/SUP], Xinxin Xiong[SUP] 1 [/SUP], Shengjun Tang[SUP] 1 [/SUP], Qinjin Dai[SUP] 1 [/SUP], Zhihai Liu[SUP] 1 [/SUP], Taorui Wang[SUP] 1 [/SUP], Xueping Gu[SUP] 2 [/SUP], Zhongcheng Zhou[SUP] 1 [/SUP]
Affiliations
Abstract
The newly emerged SARS-CoV-2 Omicron variant, sublineages BA.1 and BA.2, recently became the dominant variants of concern (VOC) with significantly higher transmissibility than any other variant appeared and markedly greater resistance to neutralization antibodies and original ancestral WA1 spike-matched vaccine. Therefore, it is urgent to develop vaccines against VOCs like Omicron. Unlike the new booming mRNA vaccine, protein vaccines have been used for decades to protect people from various kinds of viral infections and have advantages with their inexpensive production protocols and their relative stability in comparison to mRNA vaccine. Here, we show that sera from BA.1 spike protein vaccinated mice mainly elicited neutralizing antibody against BA.1 itself. However, a booster with BA.1 spike protein or a bivalent vaccine composed of D614G and BA.1 spike protein induced not only potent neutralizing antibody response against D614G and BA.1 pseudovirus, but also against BA.2, other four SARS-CoV-2 VOCs (Alpha, Beta, Gamma and Delta) and SARS-CoV-2-related coronaviruses (Pangolin CoV GD-1 and Bat CoV RsSHC014). The two recombinant spike protein vaccines method described here lay a foundation for future vaccine development for broad protection against pan-sarbecovirus. This article is protected by copyright. All rights reserved.
Keywords: BA.1; BA.2; Omicron; SARS-CoV-2; trimer; vaccine.
. 2022 May 25.
doi: 10.1002/jmv.27885. Online ahead of print.
A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity
Peng Du[SUP] 1 [/SUP], Ning Li[SUP] 1 [/SUP], Xinxin Xiong[SUP] 1 [/SUP], Shengjun Tang[SUP] 1 [/SUP], Qinjin Dai[SUP] 1 [/SUP], Zhihai Liu[SUP] 1 [/SUP], Taorui Wang[SUP] 1 [/SUP], Xueping Gu[SUP] 2 [/SUP], Zhongcheng Zhou[SUP] 1 [/SUP]
Affiliations
- PMID: 35614524
- DOI: 10.1002/jmv.27885
Abstract
The newly emerged SARS-CoV-2 Omicron variant, sublineages BA.1 and BA.2, recently became the dominant variants of concern (VOC) with significantly higher transmissibility than any other variant appeared and markedly greater resistance to neutralization antibodies and original ancestral WA1 spike-matched vaccine. Therefore, it is urgent to develop vaccines against VOCs like Omicron. Unlike the new booming mRNA vaccine, protein vaccines have been used for decades to protect people from various kinds of viral infections and have advantages with their inexpensive production protocols and their relative stability in comparison to mRNA vaccine. Here, we show that sera from BA.1 spike protein vaccinated mice mainly elicited neutralizing antibody against BA.1 itself. However, a booster with BA.1 spike protein or a bivalent vaccine composed of D614G and BA.1 spike protein induced not only potent neutralizing antibody response against D614G and BA.1 pseudovirus, but also against BA.2, other four SARS-CoV-2 VOCs (Alpha, Beta, Gamma and Delta) and SARS-CoV-2-related coronaviruses (Pangolin CoV GD-1 and Bat CoV RsSHC014). The two recombinant spike protein vaccines method described here lay a foundation for future vaccine development for broad protection against pan-sarbecovirus. This article is protected by copyright. All rights reserved.
Keywords: BA.1; BA.2; Omicron; SARS-CoV-2; trimer; vaccine.